ArticleInflammatory bowel diseases2021
Longitudinal Trajectory of Fatigue in Patients With Inflammatory Bowel Disease: A Prospective Study.
Article in Inflammatory bowel diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data.Inflammatory bowel diseases · 2023Trial
- Prevalence and Burden of Fatigue Across Disorders of Gut-Brain Interaction: Results From the Rome Foundation Global Epidemiology Study.Alimentary pharmacology & therapeutics · 2026Article
- Fatigue Trajectory During the First Year of an Inflammatory Bowel Disease Diagnosis, Results from the IBSEN III study.Digestive diseases and sciences · 2026Article
- Prevalence of Fatigue Among Inflammatory Bowel Disease Patients at a Tertiary Center in Saudi Arabia.Journal of clinical medicine · 2026Article
- Fatigue in pediatric inflammatory bowel disease: Explained by transdiagnostic and disease-focused factors.Journal of pediatric gastroenterology and nutrition · 2026Article
- Article
- PHARMACOLOGICAL TREATMENTS FOR FATIGUE IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTEGRATIVE REVIEW.Arquivos de gastroenterologia · 2026Review
- The Substantial Role of Sleep, Stress, and Physical Activity in Persistent High Levels of Fatigue in Patients With Inflammatory Bowel Disease: A Longitudinal Trajectory Study.Journal of Crohn's & colitis · 2025Article
- Modified Pulsatilla decoction ameliorates ulcerative colitis by affecting gut microbiota and metabolite profiles.Frontiers in microbiology · 2025Article
- Management of Fatigue in Inflammatory Bowel Disease: A Narrative Review.International journal of general medicine · 2025Review
- Multimodal Lifestyle Intervention Improves Fatigue in Quiescent Inflammatory Bowel Disease: A Controlled Study.Crohn's & colitis 360 · 2025Article
- All-or-Nothing Behavior and Catastrophic Thinking Predict Fatigue in Inflammatory Bowel Disease: A Prospective Cohort Study.Inflammatory bowel diseases · 2024Article
- Unraveling the fatigue puzzle: insights into the pathogenesis and management of IBD-related fatigue including the role of the gut-brain axis.Frontiers in medicine · 2024Review
- Economic Burden of Fatigue in Inflammatory Bowel Disease.Crohn's & colitis 360 · 2023Article
- Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study.Inflammatory bowel diseases · 2022Article
- Recruitment of α4β7 monocytes and neutrophils to the brain in experimental colitis is associated with elevated cytokines and anxiety-like behavior.Journal of neuroinflammation · 2022Article
- The Pharmacological Mechanism ofFrontiers in pharmacology · 2021Article
- Network Pharmacology-Based Validation of the Efficacy ofFrontiers in pharmacology · 2021Article
- Digital health technologies for monitoring and managing IBD-related fatigue: A scoping review.Digital healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundFatigue is a disabling symptom in patients with inflammatory bowel disease (IBD). Its prevalence, mechanism, and impact remain poorly understood. We determined changes in fatigue status over time and identified predictors of incident or resolving fatigue.
methodsThis was a prospective study nested within the IBD Partners cohort. Participants prospectively completed the Multidimensional Fatigue Inventory and the Functional Assessment of Chronic Illness Therapy-Fatigue at baseline, 6 months, and 12 months. A Functional Assessment of Chronic Illness Therapy-Fatigue score ≤43 defined significant fatigue. Multivariable regression models using baseline covariates were used to identify risk factors for incident fatigue at 6 months and to predict the resolution of fatigue.
resultsA total of 2429 patients (1605 with Crohn disease, 824 with ulcerative colitis) completed a baseline assessment, and 1057 completed a second assessment at 6 months. Persistent fatigue (at baseline and at 6 months) was the most common pattern, affecting two-thirds (65.8%) of patients. One-sixth (15.7%) of patients had fatigue at 1 timepoint, whereas fewer than one-fifth (18.5%) of patients never reported fatigue. Among patients not fatigued at baseline, 26% developed fatigue at 6 months. The strongest predictor of incident fatigue was sleep disturbance at baseline (odds ratio, 2.91; 95% confidence interval, 1.48-5.72). In contrast, only 12.3% of those with fatigue at baseline had symptom resolution by month 6. Resolution was more likely in patients with a diagnosis of ulcerative colitis, quiescent disease, and an absence of significant psychological comorbidity.
conclusionsFatigue is common in patients with IBD. However, only a few fatigued patients experience symptom resolution at 6 or 12 months, suggesting the need for novel interventions to ameliorate its impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.